Indaptus Therapeutics Announces $2.25 Million Private Placement

On January 12, 2025, Indaptus Therapeutics, Inc. (NASDAQ: INDP), a Delaware corporation, entered into securities purchase agreements for a private placement transaction. The agreements were made with institutional and accredited investors, resulting in aggregate gross proceeds of $2,246,500. This private placement includes the sale of 2,109,383 shares of the company’s common stock and warrants to purchase the same number of shares.

The net proceeds from this offering are intended to support the company’s research and development activities, as well as for general corporate purposes. The private placement is expected to conclude around January 15, 2025, subject to meeting customary closing conditions. Each share and accompanying warrant were priced at $1.065, with the warrants having an exercise price of $0.94 per share.

It’s important to note that the shares, warrants, and warrant shares were not registered under the Securities Act of 1933 and were offered under exemption provisions. The warrants, immediately exercisable upon issuance, will expire five years from the date of issuance, with provisions for adjustments to the exercise price.

As part of the agreements, Indaptus will file a registration statement within 60 days to register the shares and warrant shares for resale. The company is committed to making reasonable efforts to ensure the effective maintenance of this registration statement for a specified period. Paulson Investment Company, LLC acted as the exclusive placement agent for this offering.

Furthermore, a press release issued on January 13, 2025, disclosed details of the private placement pricing. The funds raised, approximately $2.25 million before fees, will be instrumental in advancing Indaptus’ research initiatives and general operations. The offering was conducted pursuant to applicable regulations to ensure compliance with securities laws.

This release emphasized that forward-looking statements involve inherent risks that may affect actual outcomes. Individuals are advised not to place undue reliance on such statements and are encouraged to consider various factors that may influence the company’s future. For additional information, including risk factors, interested parties can refer to Indaptus’ SEC filings, which detail potential uncertainties.

Press Contact:
[email protected]
Investor Relations Contact:
CORE IR
Louie Toma
[email protected]

The information included in this article is based on the recent Form 8-K filing by Indaptus Therapeutics, Inc. and related press releases.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Indaptus Therapeutics’s 8K filing here.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.